Coherus Biosciences Inc
CHRS
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
121.7% downsideOvervalued by 121.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $194.63 Million |
|---|---|
| Enterprise Value | $133.77 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.45 |
| Beta | 1.02 |
| Outstanding Shares | 136,398,303 |
Return
| Return on Equity | -192.90% |
|---|---|
| Return on Assets | -57.01% |
| Return on Invested Capital | -132.02% |
Valuation & Multiples
| P/E Ratio | -1.43 |
|---|---|
| PEG | 4.34 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.85 |
| Enterprise Value to EBIT | -0.76 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.41 |
| Debt to Equity | 0.69 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 4.8591▲ 472.62% |
|---|---|
| Total Calls | 51,100▼ 67.66% |
| Total Puts | 248,300▲ 1082.38% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 49.13%▲ 5.06% |
|---|---|
| Total Invested | $99.84M▲ 37.31% |
| Investors Holding | 160▲ 31.00% |
ESG Score
No data
About Coherus Biosciences Inc
CEO: Dennis Lanfear Relevant Senate Committees
As the primary committee for taxation, trade, and entitlement spending, it directly impacts corporate valuations through tax policy and strongly influences revenue for biological product manufacturers through Medicare pricing decisions.
This committee directly allocates federal spending to agencies like the FDA, NIH, and potentially the VA or DoD for healthcare-related purchases, thus significantly influencing funding streams and government market opportunities for Coherus Biosciences.
This committee directly regulates the FDA and NIH, which are critical for drug approval, research funding, and the overall regulatory landscape for biological product manufacturers like Coherus Biosciences.
This committee has direct oversight of antitrust laws and, crucially, intellectual property rights (patents), which are fundamental to the success and valuation of pharmaceutical and biological product companies.
Members receive classified briefings on global threats, including potential biological threats or pandemics, which can directly impact companies involved in biological product manufacturing and vaccine/therapeutic development.